Hermine A. van Duyvenvoorde

Hermine A. van Duyvenvoorde

Auto-generated profile, based on publicly available information

Hermine A. van Duyvenvoorde

Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2022 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
SOSaskia L. S. Houwen‐Van Opstal
Saskia L. S. Houwen‐Van Opstal
RTRamon O. Tak
Ramon O. Tak
MPMaaike Pelsma
Maaike Pelsma
FHFrederik van den Heuvel
Frederik van den Heuvel
HDHermine A. van Duyvenvoorde
Hermine A. van Duyvenvoorde
MWMichèl Willemsen
Michèl Willemsen
Aim: To study long‐term disease course for females with early‐onset dystrophinopathy, including common (female) symptoms, challenges in social participation, the need for care, and current healthcare management to support guideline development.Method: Twelve females with early‐onset dystrophinopathy were followed for a median period of more than 17 years (range 1–36).Results: One patient died owing to end‐stage cardiac failure. Cardiac abnormalities were observed in three of the remaining 11 participants. Respiratory function was reduced in seven of 10 participants. Fatigue, myalgia, lower back pain, and arthralgia were reported in more than six of the participants. Functional status varied from exercise intolerance to wheelchair dependency. Most or all of the 10 participants reported restrictions in participation in work (n = 10), household duties (n = 10), sports (n = 9), and education (n = 8). Only a few participants received followed‐up pulmonary (n = 2) or rehabilitation (n = 3) care.Interpretation: Females with early‐onset dystrophinopathy experience a wide range of impairments, comorbidities, limitations in activities, and restrictions in social participation. The whole spectrum should be acknowledged in the healthcare setting. Neuromuscular and cardiac follow‐up are indispensable. Additional respiratory assessment and rehabilitation care are expected to improve health status and support daily activities and participation.What this paper adds: No standard diagnostic procedures seem to exist for female patients suspected for dystrophinopathy. Female participants with early‐onset dystrophinopathy experienced a broad scope of burdening symptoms, such as fatigue, myalgia, lower back pain, and arthralgia. None of participants worked full time, all felt restricted in paid work, and most felt restricted in education. Most participants showed decreased lung function, while only one was symptomatic. Availability of rehabilitation care may improve support for daily activities and participation for females with early‐onset dystrophinopathy.

1 August 2011 in Growth Hormone & IGF Research
Verified
Journal Article
Closed access
KRK.L. Rensing
K.L. Rensing
HDH.A. van Duyvenvoorde
H.A. van Duyvenvoorde
MCMaarten J. M. Cramer
Maarten J. M. Cramer
ATArco J. Teske
Arco J. Teske
MPM. Prokop
M. Prokop
TTTh.B. Twickler
Th.B. Twickler

7 October 2025 in Neurology
Verified
Journal Article
Open access
ESEsther J. Schrama
Esther J. Schrama
ZKZaïda Koeks
Zaïda Koeks
NVNienke M. Van De Velde
Nienke M. Van De Velde
IAIris Alleman
Iris Alleman
JBJules J. van Benthem
Jules J. van Benthem
ENErik H. Niks
Erik H. Niks
Slow and highly variable disease progression in Becker muscular dystrophy (BMD) stresses the need to develop sensitive outcome measures for clinical trials. We evaluated responsiveness of different outcome measures in adult patients with BMD over 3 years and explored if the sensitivity of outcome measures can be increased by selecting on phenotype or genotype. Genetically confirmed patients with BMD were recruited via the Dutch Dystrophinopathy Database. Functional tests included North Star Ambulatory Assessment (NSAA), Timed Tests, Performance of the Upper Limb version 1.2, and pulmonary function yearly and echocardiography biennially. Mean changes and standardized response means (SRMs) were calculated per year. Outcome measures with SRM ≥0.80 were considered to have a high responsiveness to change. Two genetic subgroups-deletion of exons 45-47 and variants affecting the neuronal nitric oxide synthesis (nNOS) binding site-and one functional subgroup-NSAA between 10 and 32 at baseline-were analyzed separately. Thirty-six patients with BMD were included (mean age 41.2 years, range 18.6-67.3, 27 ambulant at baseline). A high responsiveness was observed for the rise from floor velocity (RFFv) at 3-year follow-up (SRM -0.91, n = 16), while the SRMs for the other outcome measures were <0.8 at all time points. In the functional subgroup, a high responsiveness was observed for RFFv at 1-year follow-up (SRM -0.82, n = 10), along with 4-stair climb velocity (4SCv) (SRM -1.03, n = 11) and NSAA (SRM -0.82, n = 13) at 2-year follow-up. Genetic subgroups did not significantly differ in age at loss of ambulation (LoA). Upper limb and pulmonary function were preserved beyond LoA. Decline of cardiac function was independent of skeletal muscle function. RFFv was the only outcome measure sensitive to change at 3-year follow-up. Selecting on phenotype resulted in a high responsiveness for RFFv at 1-year follow-up and for 4SCv and NSAA at 2-year follow-up. NSAA could be performed in more participants compared with RFFv and therefore seems preferable in clinical trials for ambulant patients. Despite limitations in sample size, the results suggest that clinical trials in the ambulant population could be enriched by selecting on phenotype.

23 September 2025 in Neuromuscular Disorders
Verified
Journal Article
Open access
IGIeke B. Ginjaar
Ieke B. Ginjaar
MKMarjolein Kriek
Marjolein Kriek
MHMariëtte J.V. Hoffer
Mariëtte J.V. Hoffer
RORenske Oegema
Renske Oegema
EBEllen van Binsbergen
Ellen van Binsbergen
HDHermine A. van Duyvenvoorde
Hermine A. van Duyvenvoorde
We report results of laboratory and clinical investigations in 32 cases with incidental findings of large, intragenic deletions and gains in the huge Duchenne muscular dystrophy gene using microarray analysis. The patients and prenatal cases were referred for various reasons unrelated to DMD. Multiplex Ligation-dependent Probe Amplification of the DMD gene confirmed and refined deletions (19/32) and duplications (13/32). In 18 of the 32 cases a dystrophinopathy diagnosis could be established; 10 males were found to have dystrophinopathy and eight females were diagnosed as carriers. Sixteen of them had a pathogenic deletion and two had a pathogenic duplication. In three of the 32 cases the variants remained of unknown significance. In one of the 32 cases dystrophinopathy could be excluded. In the remaining 10 cases, the variant was likely benign. Our results show the importance of additional genetic analyses and clinical follow up after potentially incidental findings of copy number variants in the DMD gene. Moreover, our study provides insight in the possible effect of intragenic copy number variants in the DMD gene. Therefore, the article can provide guidance in the interpretation of copy number variants in the DMD gene, for example once DMD is included in newborn screening.

13 June 2025 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
MHMaría Isabel Hernández
María Isabel Hernández
VGVivian Gallardo
Vivian Gallardo
NUNancy Unanue
Nancy Unanue
HDHermine van Duyvenvoorde
Hermine van Duyvenvoorde
MMMaría Verónica Mericq
María Verónica Mericq
Article Identification of pathogenic ACAN variants in healthy children with normal height and advanced bone age was published on August 28, 2025 in the journal Journal of Pediatric Endocrinology and Metabolism (volume 0, issue 0).